Merck Sharp & Dohme Corp. [clinicaltrials_resource:bd932dcb36d27f98f1bb6129a9c0d723]
Toll Free Number [clinicaltrials_resource:02ea8a98059036fbde3ad54be37ae9a9]Medical Director [clinicaltrials_resource:0576fd59ccdd1a865d0ec28c86108d13]Amy Schaberg, BSN [clinicaltrials_resource:05938795258e8be91c96bb76466b0fd1]Medical Director [clinicaltrials_resource:07acaee0deb52d7d3f40dac4da4f1b5c]Medical Director [clinicaltrials_resource:0db754e2fe5c95c73adaede69099dc23]Medical Director [clinicaltrials_resource:1a2f1e77e01b407187985218ff0c2475]Medical Director [clinicaltrials_resource:1ab59ad241281446fdb2a3c50514981d]Study Director [clinicaltrials_resource:1c43ff29bf7cdfaf6383480a2582a79d]Medical Monitor [clinicaltrials_resource:27195d211abb9273c80c26c3f8388190]Medical Director [clinicaltrials_resource:300bc9d55b4fe9c70ffa5b5e4026b5ab]Siu-Long Yao [clinicaltrials_resource:32d2e873178826c23bd68c9e094300d0]Medical Director [clinicaltrials_resource:3dd21db1189fcebb55c6be13273826e0]Medical Director [clinicaltrials_resource:40a67f92689cc2448e30b55e26eaccf7]Klaus Beck, MD, PhD [clinicaltrials_resource:40e58c561b012516c19faef1bc9af890]Medical Director [clinicaltrials_resource:4c3bd2ac1798a5263c277c8bb33822f1]Medical Director, Study Director, Merck [clinicaltrials_resource:518e4cd92f5483a1eee84aa60fbbde02]Medical Director [clinicaltrials_resource:5610e120353d6352c5fc21e617bb9ed8]Medical Director [clinicaltrials_resource:5786bc0984f946765b099cfdaf6fddfb]medical Monitor [clinicaltrials_resource:5ef8c5271bcbda2e509699a1e4785cc3]Saiid Davari [clinicaltrials_resource:7fa192aeae6c4b9c1a22bb7d55e754f9]Medical director [clinicaltrials_resource:8c2f2c6bb0dc9a803933db7c57735006]Medical Director [clinicaltrials_resource:8e4f70d7238edbd4614b0562f893ab88]Medical Monitior [clinicaltrials_resource:959923b2387ac1c488edfe42691d0829]Reza Haque, MD [clinicaltrials_resource:9c6b649aff6b7faf2f1f912b5bf9a343]Medical Director [clinicaltrials_resource:ad43f76726c5b9b210530c8a039b5f5d]Medical Director [clinicaltrials_resource:b74297f759bad147d94304cc1503fb99]Medical Director [clinicaltrials_resource:b7666d8c52dc4b91a832a8007b56c11b]Medical Director [clinicaltrials_resource:c33203cdecf1871ddee3b4ff367be5d4]Donald Kellerman, PharmD [clinicaltrials_resource:c5dad146e91d8a3b79421bbaeb3045c6]Reza Haque [clinicaltrials_resource:c70c9a06131ebaeb8fe7b8f6d501c37c]Clinical Director [clinicaltrials_resource:d4ab6949166d1bab52d6c20f96415b72]Ariel Teper, MD [clinicaltrials_resource:eab786720559286ff92803c99c1b5a86]Medical Director [clinicaltrials_resource:ec73f5a893cf23b66634157d3f0df275]Medical Director [clinicaltrials_resource:ecfabdd48d1684a8b9821239cfbfc014]
affiliation [clinicaltrials_vocabulary:affiliation]
A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine [clinicaltrials:NCT00000628]A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors [clinicaltrials:NCT00002235]Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease [clinicaltrials:NCT00056147]clinicaltrials:NCT00060632Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED) [clinicaltrials:NCT00060645]Efficacy and Safety of Nasonex vs. Placebo in Subjects With SAR and Concomitant Asthma (Study P03280) [clinicaltrials:NCT00070707]clinicaltrials:NCT00086125Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED) [clinicaltrials:NCT00087451]clinicaltrials:NCT00089895clinicaltrials:NCT00091572Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED) [clinicaltrials:NCT00093080]clinicaltrials:NCT00095576AP23573 in Patients With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(8669-017)(COMPLETED) [clinicaltrials:NCT00110188]Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED) [clinicaltrials:NCT00112372]AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED) [clinicaltrials:NCT00122343]An Investigational Drug Co-Administered With Insulin in Patients With Type 2 Diabetes (0478-065) [clinicaltrials:NCT00130806]Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272) (COMPLETED) [clinicaltrials:NCT00139932]9 Week Extension Study of Asenapine and Olanzapine in Treatment of Mania (P07007)(COMPLETED) [clinicaltrials:NCT00143182]3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008) [clinicaltrials:NCT00159744]clinicaltrials:NCT00159783Sisomicin Cream Vs Nadifloxacin Cream in Primary Pyodermas (Study P04460) [clinicaltrials:NCT00202891]clinicaltrials:NCT00254982clinicaltrials:NCT00266799clinicaltrials:NCT00266812Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015) [clinicaltrials:NCT00288431]clinicaltrials:NCT00302081clinicaltrials:NCT00319449clinicaltrials:NCT00358527clinicaltrials:NCT00367237Effects of Low-dose Maintenance Peg Interferon Alfa-2b Therapy Versus Supportive Care in Patients With Cirrhotic Hepatitis C With HIV (Study P04371) [clinicaltrials:NCT00381017]clinicaltrials:NCT00381485clinicaltrials:NCT00383240clinicaltrials:NCT00383435clinicaltrials:NCT00383552clinicaltrials:NCT00383721clinicaltrials:NCT00394589Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin [clinicaltrials:NCT00395421]Hormonal Contraception in Healthy Young Men (P42306)(COMPLETED)(P06057) [clinicaltrials:NCT00403793]clinicaltrials:NCT00413972clinicaltrials:NCT00423488
collaborator [clinicaltrials_vocabulary:collaborator]
A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine [clinicaltrials:NCT00000628]A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT/3TC [clinicaltrials:NCT00002155]The Effectiveness of Indinavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients With No Symptoms of Infection [clinicaltrials:NCT00002179]A Multicenter, Open-Label, Randomized, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate, 800 Mg q 8 h Versus 1,200 Mg q 12 h in Combination With Zidovudine and 3TC [clinicaltrials:NCT00002208]Indinavir Plus Efavirenz Plus Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Had Success With Nelfinavir [clinicaltrials:NCT00002220]A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors [clinicaltrials:NCT00002235]Safety and Effectiveness of an Anti-HIV Drug Combination Taken Twice Daily [clinicaltrials:NCT00002241]A Study of L-735,524 in HIV-Positive Children and Adolescents [clinicaltrials:NCT00002351]A Study of Indinavir Sulfate Given Together With Stavudine to HIV-Positive Patients [clinicaltrials:NCT00002354]Safety and Effectiveness of an Anti-HIV Drug Combination in HIV-Positive Patients Who Have Failed Previous Treatment With Protease Inhibitors [clinicaltrials:NCT00002361]Safety and Effectiveness of Giving Indinavir and Nelfinavir to HIV-Infected Patients [clinicaltrials:NCT00002375]The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients [clinicaltrials:NCT00002376]Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia [clinicaltrials:NCT00002386]The Safety and Effectiveness of Indinavir Sulfate Plus Efavirenz [clinicaltrials:NCT00002387]A Comparison of Two Dose Levels of Indinavir Combined With Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients [clinicaltrials:NCT00002406]A Study to Compare the Safety and Effectiveness of Indinavir Combined With Stavudine and Lamivudine [clinicaltrials:NCT00002424]A Study to Compare the Effectiveness of Two Anti-HIV Drug Combinations [clinicaltrials:NCT00002430]The Safety and Effectiveness of MK-639 and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs [clinicaltrials:NCT00002443]Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV Drugs [clinicaltrials:NCT00002451]A Study on the Safety and Effectiveness of L-756423 Plus Indinavir in HIV-Positive Patients Who Have Previously Taken Indinavir [clinicaltrials:NCT00002452]SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084) [clinicaltrials:NCT00002960]Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer [clinicaltrials:NCT00003880]The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment [clinicaltrials:NCT00005118]Safety and Effectiveness of Giving L-743,872 to Patients With Thrush That Has Not Been Cured With Fluconazole [clinicaltrials:NCT00005920]A Study of the Side Effects of L-743,872 in Men With Candidal Esophagitis [clinicaltrials:NCT00005921]The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease [clinicaltrials:NCT00006187]A Study in Adult and Pediatric Patients With Cystic Fibrosis [clinicaltrials:NCT00034515]Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P02095) [clinicaltrials:NCT00034632]Prophylaxis Trial in High Risk Allogenic Stem Cell Transplant Recipients With Graft vs. Host Disease [clinicaltrials:NCT00034645]Open Label Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P00041) [clinicaltrials:NCT00034658]PK/PD Study of Posaconazole for Empiric Treatment of Invasive Fungal Infections in Neutropenic Patients or Treatment of Refractory Invasive Fungal Infections (Study P01893) [clinicaltrials:NCT00034671]Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701) [clinicaltrials:NCT00034684]Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143) [clinicaltrials:NCT00034697]Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063) [clinicaltrials:NCT00034944]Treatment of Patients With Major Depressive Disorder With MK0869 [clinicaltrials:NCT00034983]Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059) [clinicaltrials:NCT00035009]Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED) [clinicaltrials:NCT00035048]Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED) [clinicaltrials:NCT00035282]Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061) [clinicaltrials:NCT00035295]Phase III PEG-Intron in HIV-infected Patients (Study P00738) [clinicaltrials:NCT00035360]
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
organization [clinicaltrials_vocabulary:organization]
SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084) [clinicaltrials:NCT00002960]Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer [clinicaltrials:NCT00003880]A Study in Adult and Pediatric Patients With Cystic Fibrosis [clinicaltrials:NCT00034515]Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P02095) [clinicaltrials:NCT00034632]Prophylaxis Trial in High Risk Allogenic Stem Cell Transplant Recipients With Graft vs. Host Disease [clinicaltrials:NCT00034645]Open Label Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P00041) [clinicaltrials:NCT00034658]PK/PD Study of Posaconazole for Empiric Treatment of Invasive Fungal Infections in Neutropenic Patients or Treatment of Refractory Invasive Fungal Infections (Study P01893) [clinicaltrials:NCT00034671]Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701) [clinicaltrials:NCT00034684]Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143) [clinicaltrials:NCT00034697]Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063) [clinicaltrials:NCT00034944]Treatment of Patients With Major Depressive Disorder With MK0869 [clinicaltrials:NCT00034983]Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059) [clinicaltrials:NCT00035009]Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED) [clinicaltrials:NCT00035048]Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED) [clinicaltrials:NCT00035282]Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061) [clinicaltrials:NCT00035295]Phase III PEG-Intron in HIV-infected Patients (Study P00738) [clinicaltrials:NCT00035360]Study of INS365 Ophthalmic Solution in a Controlled Adverse Environment in Patients With Dry Eye [clinicaltrials:NCT00037661]clinicaltrials:NCT00039871Safety and Efficacy Study of IL-10 (Tenovil TM) in the Prevention of Post-ERCP Acute Pancreatitis (Study P02580)(TERMINATED) [clinicaltrials:NCT00040131]Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination With Gemcitabine and Cisplatin in Advanced Cancer (Study P01499)(TERMINATED) [clinicaltrials:NCT00040534]Farnesyl Protein Transferase Inhibitor (FPTI) in Combination With Docetaxel in Advanced Solid Tumors (Study P01964)(COMPLETED) [clinicaltrials:NCT00040547]Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073) [clinicaltrials:NCT00042029]Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899) [clinicaltrials:NCT00044486]Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED) [clinicaltrials:NCT00048594]Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED) [clinicaltrials:NCT00048607]clinicaltrials:NCT00048724clinicaltrials:NCT00049842Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED) [clinicaltrials:NCT00050336]Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease [clinicaltrials:NCT00056147]Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201) [clinicaltrials:NCT00060476]clinicaltrials:NCT00060632Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED) [clinicaltrials:NCT00060645]Efficacy and Safety of Nasonex vs. Placebo in Subjects With SAR and Concomitant Asthma (Study P03280) [clinicaltrials:NCT00070707]Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530) [clinicaltrials:NCT00073450]Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED) [clinicaltrials:NCT00074529]Temozolomide for Treatment of Brain Metastases From Non-Small Cell Lung Cancer (Study P03247) [clinicaltrials:NCT00076856]MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis (0991-037) [clinicaltrials:NCT00076869]An Investigational Drug Study to Treat Respiratory Symptoms Associated With Respiratory Syncytial Virus (RSV) Bronchiolitis (0476-272) [clinicaltrials:NCT00076973]Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097) [clinicaltrials:NCT00080444]Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480) [clinicaltrials:NCT00081510]
source [clinicaltrials_vocabulary:source]
Merck Sharp & Dohme Corp. [clinicaltrials_resource:bd932dcb36d27f98f1bb6129a9c0d723]
Bio2RDF identifier
bd932dcb36d27f98f1bb6129a9c0d723
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:bd932dcb36d27f98f1bb6129a9c0d723
organization [clinicaltrials_vocabulary:organization]
identifier
clinicaltrials_resource:bd932dcb36d27f98f1bb6129a9c0d723
title
Merck Sharp & Dohme Corp.
@en
type
label
Merck Sharp & Dohme Corp. [clinicaltrials_resource:bd932dcb36d27f98f1bb6129a9c0d723]
@en